slides · global inventory
Expose Contradiction
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 14,162
Current window 10,261-10,290
Pages 473
Rows per page 30
Slide function
10,261-10,290 of 14,162
250
The slide uses direct quotes from a KOL to undermine the credibility of the clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
251
The slide uses a Q&A format to highlight inconsistencies in clinical trial reporting.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
252
The slide uses direct quotes from a KOL to undermine the company's marketing narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
253
The slide uses a quote to undermine the credibility of the company's clinical trial data by highlighting the difference between controlled trial environments and real-world application.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
255
The slide uses direct quotes to frame the company's actions as predatory and unethical.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
256
The slide uses direct quotes from a KOL to frame the company's town hall as an 'infomercial' that avoids difficult questions.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
257
The slide uses a Q&A format to present expert testimony that undermines the value proposition of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
259
The slide uses a 'Miller XR' moniker to highlight the perceived over-reliance on a single individual.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
260
The slide uses red boxes to highlight the name 'Jennifer Miller' across different study documents to emphasize her consistent involvement.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
261
The slide uses a quote to highlight potential ethical or professional concerns regarding a physician's promotion of a drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
264
The slide uses direct quotes and expert testimony to build a case against the credibility of a key opinion leader (Miller).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
265
The slide uses a screenshot of a tweet as primary evidence to expose the subject's promotional behavior.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
266
Uses press release excerpts to establish a pattern of behavior or conflict of interest.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
267
The slide uses a combination of narrative text, a screenshot of a YouTube video, and snippets of press articles to build a case of poor judgment or questionable association.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
268
The slide uses a direct quote to highlight a conflict of interest or professional disagreement regarding medical standards.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
269
The slide uses direct quotes from an Anthem VP to undermine the product's market viability.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
270
The slide uses highlighted text to emphasize key parts of the expert interview transcript.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
271
The slide uses direct quotes to expose the insurer's strategy of forcing generic/compounded substitution to save costs.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
273
The slide uses expert quotes to undermine the perceived market opportunity for Soleno.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
274
The slide uses a Q&A transcript format to undermine the commercial viability of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
275
The slide uses direct quotes from a researcher to undermine the perceived positive sentiment of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
276
The slide uses a Q&A format to highlight the tension between corporate marketing pressure and scientific/ethical boundaries.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
277
The slide uses a Q&A format to highlight negative expert sentiment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
279
The slide uses highlighted quotes from a former senior medical affairs employee to undermine the commercial viability of Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
281
The slide uses a 'villain/expert critique' format to undermine the target company's drug efficacy and pricing.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
282
The slide uses highlighted text to draw attention to key negative sentiments from the KOL.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
284
The slide uses a Q&A transcript format to highlight expert skepticism and safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
285
The slide uses a Q&A format to present expert opinion as evidence of safety risks.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
286
The slide uses highlighted text to emphasize key concerns about cardiac risk, genetic subtypes, and the drug's unknown mechanism of action.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
287
The slide highlights a potential safety risk identified by a KOL regarding the drug's mechanism of action.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit